Objectives: This study aimed to determine the steady-state serum and alveolar concentrations of linezolid administered by continuous infusion to critically ill patients with ventilator-associated pneumonia (VAP).
Introduction
Linezolid is indicated and recognized as an alternative to glycopeptides in the treatment of Gram-positive ventilator-associated pneumonia (VAP), mainly caused by oxacillin-resistant Staphylococcus aureus.
1,2 The pharmacokinetics and pharmacodynamics of linezolid have been widely studied in in vitro and experimental models and in healthy volunteers. 1 In a rabbit S. aureus endocarditis model, intermittent dosing had an in vivo bacteriostatic effect but switching to continuous infusion at the same dose led to in vivo bactericidal activity, suggesting that continuous infusion could be an appropriate alternative for the treatment of severe infections. 3 In a recent study performed in infected critically ill patients, continuous infusion has shown theoretical advantages over intermittent infusion according to pharmacokinetic/pharmacodynamic parameters. 4 However, to date, no data concerning the alveolar diffusion of linezolid administered in continuous infusion are available. Therefore, we conducted a study to determine the steady-state serum and alveolar concentrations and pharmacokinetics of 1200 mg of intravenous linezolid administered daily in continuous infusion to critically ill patients with VAP.
Patients and methods
This was a prospective, open-label, single-centre study approved by the local Ethics Committee. Prior to inclusion in the study, all patients or their closest relative provided written informed consent. Critically ill adult patients on mechanical ventilation were considered eligible for inclusion when suspected of having VAP. The patients were excluded from the study if they were allergic to oxazolidinone antibiotics, exhibited renal dysfunction defined by a calculated creatinine clearance (using 24 h urine) of ,40 mL/min. Before initiation of therapy, specimens for microbiological diagnosis were obtained using a plugged telescoping catheter (Combicath w , Plastimed, St-Leu-La-Forêt, France) from all patients, as previously described. 5 Due to the high-risk pathogens usually encountered in late-onset VAP, linezolid was then administered as empirical therapy with the addition of an antipseudomonal b-lactam and amikacin until identification of the pathogen and determination of its antibiotic susceptibility.
All subjects received a 1 h intravenous infusion of 600 mg of linezolid as a loading dose followed by 1200 mg/day by continuous infusion. All samples for linezolid concentration determinations were obtained at steady state after 2 days of therapy. One blood sample was collected from each patient and immediately centrifuged at 3000 rpm for 5 min. The serum was removed and stored at 2808C until analysed. Simultaneously with blood sampling, each subject underwent one standardized mini-bronchoalveolar lavage (mini-BAL) procedure, as previously described, which has been advocated as a reliable method for antibiotic measurement in epithelial lining fluid (ELF). 6 A standard bronchial brush tube (Combicath w ) was inserted in the endotracheal tube and used to perform a mini-BAL with 40 mL of sterile 0.9% normal saline solution. The aspirate was immediately centrifuged at 3000 rpm for 5 min and a single aliquot of supernatant was separated and frozen for the urea assay. The remaining volume was frozen at 2808C until the assays were performed. All blood and BAL samples were assayed within 6 months from the time of their collection.
Linezolid concentrations in serum and BAL were measured simultaneously by an HPLC method validated in our laboratory. 7 As previously described, the concentration of linezolid in ELF (LZD ELF ) was determined as follows, using urea as an endogenous marker:
where LZD BAL is the measured concentration of linezolid in BAL fluid, urea serum is the concentration of urea in serum, and urea BAL is the concentration of urea in the BAL fluid.
Observed steady-state concentrations (C ss ) were determined at the pharmacokinetic steady state during continuous infusion in serum and ELF. The total body clearance (CL T ) was estimated by using the following equation CL T ¼K 0 /C ss , where K 0 is the infusion rate. The AUC from time zero to the end of the dosing interval (AUC 0 -12 ) was calculated as AUC 0 -12 ¼(dose×F)/CL T , where F¼1 for intravenous administration. The daily AUC was calculated as AUC 0 -24 ¼AUC 0 -12 ×2 for serum and ELF.
Results
Twelve adult subjects with late-onset VAP completed the study. Patients' characteristics at enrolment appear in Table 1 . Linezolid administration and mini-BAL procedures were well tolerated and no adverse effects were observed. After determination of the susceptibility of the causative pathogen, the antibiotic combination with the narrowest spectrum was administered whenever possible. Figure 1 shows the individual steady-state serum and ELF linezolid concentrations. The median (IQR) linezolid C ss values were 7.1 (6.1 -9.8) and 6.9 (5.8 -8.6) mg/L in serum and ELF, respectively, and the median (IQR) linezolid AUC 0 -24 values were 169 (146 -235) and 164 (139 -202) mg . h/L in serum and ELF, respectively, corresponding to a median (IQR) linezolid alveolar diffusion of 97% (80%-108%) ( Table 2) .
Discussion
This is the first known study to report the steady-state serum and alveolar concentrations and the alveolar percentage penetration of 1200 mg of linezolid administered daily in continuous infusion to critically ill patients with VAP. Our study shows satisfactory results, with linezolid concentrations in both serum and ELF ( 7 mg/L) almost 2-fold higher than the susceptibility breakpoint for oxacillin-resistant S. aureus (4 mg/L) for 100% of the time.
The ELF concentrations of linezolid were investigated after oral drug administration in healthy volunteers. 8 Assuming a bioavailability of 100%, the authors demonstrated that ELF concentrations ranged from 10.2 to 45.9 mg/L (with an average value of 24.3 mg/L) immediately before the next dose, achieving high values for AUC/MIC and the time during which linezolid was above the MIC (T .MIC ). Although the present and previous studies enrolled different subjects (VAP patients versus healthy volunteers) who received linezolid by different routes of administration, this might raise the question of whether continuous infusion of linezolid may be used when treating pneumonia or should be applied for other infections. However, the pharmacokinetics/ pharmacodynamics and tissue penetration of linezolid have been studied extensively in various models. 4, 5, 9, 10 These studies suggest that the administration of linezolid during the treatment Data are expressed as median (IQR), n/n or n (%). of severe nosocomial infections provides serum and tissue concentrations in excess of the MIC for most of the targeted pathogens.
In a previous study performed in critically ill patients with VAP, we have shown that the intravenous administration of 600 mg of linezolid twice daily provides a linezolid alveolar diffusion of 100% and concentrations exceeding the MICs for the targeted pathogens in both serum and ELF. 5 However, in this study the intermittent infusion of linezolid provided serum and alveolar concentrations exceeding the susceptibility breakpoint for oxacillin-resistant S. aureus (4 mg/L) for only 75% of the time.
The clinical pharmacodynamics of linezolid have been published in a retrospective analysis conducted in adult patients with numerous comorbid conditions and complicated microbiologically documented infection caused by Gram-positive strains treated with 600 mg of oral or intravenous linezolid twice daily. 11 This study showed that higher success rates were achieved when T .MIC exceeded 80% and when AUC/MIC values exceeded 100. In our study, continuous infusion provided serum and ELF concentrations 2-fold the susceptibility breakpoint for 100% of the time, which seems to optimize this route of administration by providing T .MIC ¼ 100% even for strains with MICs as high as 4 mg/L.
Our study has some limitations, however. Due to the high clinical success rate observed in our small number of patients, the heterogeneity of the identified pathogens and the use of other antimicrobial agents in combination (imipenem or piperacillin/tazobactam and amikacin), no clear association could be established between clinical outcome and linezolid serum or alveolar pharmacokinetic/pharmacodynamic parameters. Besides, considering the median AUC 0 -24 of 165 mg . h/L observed in both serum and ELF in the current study, AUC/MIC ratios of .100 might not be achieved for pathogens with MICs ≥2 mg/L in critically ill patients with VAP, whereas T .MIC of 100% may be obtained in both serum and ELF for pathogens with MICs as high as 4 mg/L. This difference might be explained by the fact that the AUC/MIC threshold of 100 was determined with 600 mg of oral or intravenous linezolid twice daily in severely debilitated infected patients with numerous comorbid conditions and might be different when using continuous infusion. 9 Therefore, the optimal pharmacokinetic/pharmacodynamic parameter in critically ill patients with VAP treated with 1200 mg of linezolid daily in continuous infusion is still unclear and its determination needs further study. Moreover, the use of ELF concentrations as a surrogate marker of tissue concentrations is debatable and information on clinical outcome in relation to ELF concentration is still missing in the current literature.
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Another limitation of our study is that the relatively small number of patients does not permit extrapolation to any critically ill patient with Gram-positive VAP, who might present different renal functions or underlying conditions influencing the serum and tissue distribution of linezolid, such as continuous haemofiltration or sepsis. Furthermore, some other factors might be taken into account in the interpretation of our results, such as protein binding (although this is relatively low), cellular uptake or contamination. 10 Moreover, our results may not be applicable to critically ill populations other than that studied here, such as morbidly obese or paediatric patients. Besides, the local epidemiology of causative pathogens encountered in VAP and their pattern of susceptibility to linezolid should be known before administering this agent as empirical therapy, since narrowerspectrum and less expensive agents might be proposed as firstline therapy depending on local conditions. 
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Conclusions
In conclusion, our study shows that continuous infusion of linezolid in critically ill patients with VAP provides satisfactory serum and alveolar levels in this particular subset of patients, with an alveolar diffusion of 100% and concentrations exceeding almost twice the susceptibility breakpoint for S. aureus (4 mg/L) in both serum and ELF for 100% of the time. This suggests that 1200 mg of intravenous linezolid administered by continuous daily infusion to critically ill patients with VAP should be effective against organisms with MICs as high as 2 -4 mg/L. However, further study is needed to determine not only the optimal pharmacokinetic/pharmacodynamic target when using linezolid in continuous infusion during the treatment of VAP but also the clinical benefit of continuous infusion in comparison with standard intermittent infusion.
